Hypersensitivity Flashcards

1
Q

How to determine if B cell monoclonal proliferation?

A

including flow cytometry, serum protein electrophoresis with immunofixation electrophoresis (e.g. monoclonal spike in myeloma), kappa and lambda immunostaining, and kappa and lambda in situ hybridization study, B lymphocyte immunoglobulin gene arrangement analysis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

How to determine if T cell monoclonal?

A

TCR gene rearrangement analysis

flow cytometry studies, or by analysis of immunostains for T lymphocyte markers on paraffin embedded tissue.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Flow cytometry performed on what

A

fresh, unfixed tissue

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

5 pillars of cancer treatment

A
Surgery
Chemotherapy
Radiation
Targeted therapies
Immunotherapy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Protein serum electrophoresis - what do you see in cirrhosis, myeloma, waldenstrom’s macroglobulinemia

A

In cirrhosis, see elevated gamma fraction but with kappa and lambda.
In myeloma, see only kappa and peak in gamma.
In Waldenstrom’s macroglobulinemia - kappa light chain restriction, M speak monoclonal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Define hypersensitivity reactions

A

Individuals previously exposed to an antigen are said to be sensitized; upon repeat exposure(s), some individuals will develop an excessive, injurious pathologic immune reaction to the antigen. These pathologic immune reactions are called hypersensitivity reactions, and are the basis of the pathology associated with immune diseases.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

type 1 hs

A

immediate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

type 2 hs

A

antibody-mediated

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

type 3 hs

A

immune complex-mediated

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

type 4 hs

A

cell-mediated

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

type 1 hs prototypic disorder

A

anaphylaxis, allergies, bronchial asthma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

type 2 hs prototypic disorder

A

autoimmune hemolytic anemia, goodpastures

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

type 3 hs prototypic disorder

A

SLE, serum sickness, arthus

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

type 4 hs prototypic disorder

A

contact dermatitis, MS, DM 1, RA, IBD, tb

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Type 1 hs definition

A

rapid immunologic reaction occurring within minutes after an antigen combines with antibody bound to mast cells in individuals previously sensitized to the antigen (allergic reaction).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Type 1 hs mediated by

A

is typically mediated by IgE antibody-dependant activation of mast cells, with degranulation and release of mast cell contents.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Type 1 hs steps

A

Sensitization (initial exposure to antigen – activation of B cells w/ production of IgE attaching to mast cells)
Repeat exposure causing mast cell degranulation
Late phase reaction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What do mast cells release

A

release of chemical mediators, causing vasodilation, vascular leakage, smooth muscle spasm, and recruitment of leukocytes, particularly eosinophils.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What do eosinophils release

A

secrete major basic protein and eosinophil cationic protein, which are toxic to epithelial cells.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

what is late phase reaction

A

Activated eosinophils and neutrophils also activate mast cells to release mediators, amplifying and sustaining the inflammatory response without additional exposure to the triggering antigen (late phase reaction).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

atopy

A

predisposition to develop immediate hypersensitivity reacti

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Antigens that elicit allergic reactions

A

allergens

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

hygiene hypothesis

A

Incidence of allergic diseases is increasing. As this seems to be related to decreasing infections in early life, some have postulated that improved hygiene has diminished exposure to microbial antigens in early life which “educate” the immune system, setting the stage for subsequent pathologic allergic responses later in life

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Mediators of immediate hypersensitivity (of type 1)

A

vasoactive amines, lipid mediators

25
Q

Mediators of late phase reaction (of type 1)

A

cytokines

26
Q

Non-Atopic allergy

A

In some individuals, immediate hypersensitivity reactions are triggered by temperature extremes and exercise (non-atopic allergy) and do not involve T helper cells or IgE. In these cases it is believed that the mast cells are abnormally sensitive to activation by various non-immune stimuli.

27
Q

Examples of local allergic reactions

A

allergic rhinitis, sinusitis
bronchial asthma
Food allergies (allergic gastroenteritis)
Urticaria (often a manifestation of a systemic reaction)

28
Q

systemic allergic response

A

anaphylaxis

29
Q

anaphylaxis characterized by

A

fall in blood pressure with vascular shock, bronchospasm and laryngeal edema with difficulty breathing (massive mast cell activation).

30
Q

death from anaphylaxis

A

to asphyxiation from upper airway edema or acute respiratory failure due to bronchial constriction and obstruction, and/or shock with cardiovascular collapse.

31
Q

desensitization therapy

A

repeated injections of the allergen in increasingly greater amounts resulting in the production of IgG antibodies that can attach to allergens and prevent them from binding to mast cells.

32
Q

type II caused by

A

antibodies that react with normal or altered cell surface antigens, or with antigens in the extracellular matrix. This can cause disease by destroying cells, triggering inflammation, or by interfering with normal function.

33
Q

mechanisms of antibody-mediated injury

A

opsonization and phagocytosis
complement and Fc receptor
Antibody-mediated cellular dysfunction (block receptors etc)

34
Q

myasthenia gravis

A

ach receptor (Type II)

35
Q

Graves

A

TSH receptor (Type II)

36
Q

Goodpasture syndrome

A

basement membrane in glomeruli of kidney (type 2)

see uniform distribution of ab to the uniformly distributed basement membrane proteins

37
Q

pemphigus vulgaris

A

desmogleins 1 and 3 found in desmosomes –> blistering (type II)

38
Q

type III cause by

A

immune complexes

Caused by deposition of antigen-antibody complexes which elicit inflammation at the sites of deposition.

39
Q

type III pathologic reaction begins when

A

antigen in the circulation combines with antibody in the circulation, and the circulating immune complexes are deposited in vessel walls. In some instances, the complexes can form at extravascular sites where the antigen has been “planted” previously (called in situ immune complex deposition).
Get lumpy-bumpy fashion

40
Q

lumpy-bumpy vs. smooth distribiton

A

lumpy-bumpy in Type III *because that’s where the antigen-ab complex lands (random, also why random/varied presentations)

smooth in Type II *because that’s how antigen was already set up

41
Q

locations for Type III hs

A

The sites of involvement can be systemic or localized. Blood vessels, as well as organs where blood is filtered to form other fluids, such as kidneys and synovium, are common sites of injury. Thus patients may develop symptoms related to vasculitis, glomerulonephritis, and arthritis.

42
Q

Key steps in immune-complex mediated hs

A

Immune complex formation

Immune complex deposition

Immune complex-mediated inflammation and tissue injury.

43
Q

Low levels of C3 indicate

A

active disease (type III hs) because complement is consumed as part of pathogenic process

44
Q

levels of what can be used to measure immune-complex mediated disease

A

C3

45
Q

examples of type III hs

A

SLE, poststreptococcal glomerulonephritis, polyarteritis nodosa, reactive arthritis, serum sickness, arthus reaction

46
Q

type Iv cause by

A

Caused by inflammation resulting from cytokines produced by CD4+ T lymphocytes and cell killing by CD8+ T lymphocytes (no antibodies involved).
CD4+ or CD8+ T lymphocytes are sensitized to exogenous or endogenous antigens. The resultant T cell immune response results in cell or tissue injury.

47
Q

2 mechanisms of T cell mediated (type 4) hs

A

CD4+ T cell-mediated inflammation

CD8+ T cell-mediated cytotoxicity

48
Q

CD4+ T Cell mediated inflammation

A

Repeat exposure of antigen, CD4+ T cells secrete cytokines –> recruit and activate macrophages and neutrophils –> tissue injury

49
Q

examples CD4+ T cell mediated inflammation

A

delayed-type hypersensitivity (tissue reaction to antigens given to immune individuals)
Antigen given into skin of previously immunized individual –> detectable skin reaction w/in 24-48 hours
ie. Mantoux

50
Q

CD8+ T cell mediated cytotoxicity

A

CD8+ cytotoxic T cells kill antigen-expressing target cells.

51
Q

examples of CD4+ cytokine mediated inflammation

A

mantoux, contact dermatitis, MS, IBD

52
Q

Examples of CD8+ cytotoxic killing

A

DM I and graft rejection

53
Q

alternative to the mantoux

A

quantaferon: look at the cytokines - take cells, expose to TB - look for cytokines

54
Q

granuloma trying to, activates what

A

It is a cellular attempt to contain an offending agent which is difficult to eradicate. Typically there is strong activation of T lymphocytes, leading to activated macrophages, resulting in tissue injury.

55
Q

granulomas contain

A

A granuloma is a focus of chronic inflammation consisting of a microscopic aggregation of macrophages that are transformed into epithelial-like cells (called histiocytes), with variable numbers of lymphocytes and plasma cells. The epithelial-like cells (histiocytes) may also fuse to form multi-nucleated giant cells.

56
Q

foreign body granulas

A

see foreign material within histiocytes/giant cells, sometimes called “foreign body giant cell reaction” by pathologists

57
Q

caseating granuloma

A

granulomas that induce cell mediated immune response with central necrosis; these are usually associated with infection (e.g. mycobacterial, fungal infections)

58
Q

non-caseating granulomas

A

: granulomas that induce cell mediated immune response without central necrosis (e.g. Sarcoidosis, Crohn’s disease)